Treating drug dependence with the aid of ibogaine: a qualitative study

Illicit and legal drug use together account for a substantial global burden of disease, with dependence affecting tens to hundreds of millions of people and contributing markedly to disability-adjusted life years. Existing behavioural and pharmacological treatments show variable effectiveness across substances, and there is a notable absence of effective pharmacotherapies for psychostimulants such as cocaine and crack. Ibogaine, an alkaloid from Tabernanthe iboga, produces prolonged modified states of consciousness and has been reported in anecdotes, preclinical studies and small clinical series to reduce drug use and craving; its metabolite noribogaine is long-lived and the compound interacts with multiple neural targets while also carrying cardiotoxic risk via QTc prolongation. Ekman Schenberg and colleagues set out to evaluate whether a treatment combining hospital-administered ibogaine with cognitive-behavioural psychotherapy produced benefits beyond reductions in consumption. Specifically, the study tested the hypothesis that this combined intervention would yield improvements in secondary outcomes recommended for substance‑use treatment evaluation: psychosocial functioning, self-efficacy, craving, family support, network/social support, and quality of life. The investigators approached this question using a directed (deductive) qualitative content analysis of semi-structured interviews with treated patients in Brazil.

This was a qualitative study using a directed approach to content analysis, which begins with existing theory or prior knowledge to define categories for coding. The analytic frame was based on six secondary outcome domains recommended for drug‑dependence interventions: psychosocial functioning, self‑efficacy, craving, family support, network/social support, and quality of life. Researchers constructed a structured matrix from these categories and coded interview material that fit the pre-established frame. Participants comprised 22 patients meeting DSM‑IV‑TR criteria for drug dependence, recruited by clinic staff where the cognitive therapy was delivered. The sample included 7 women and 15 men, ages 22–53 (mean 33), with age of first drug use averaging 15 years. Primary drugs were cocaine for 10 patients (45%) and crack cocaine for 9 patients (41%); one patient each reported alcohol, cannabis or heroin as the primary problem. Most participants (91%) had failed previous treatments and 73% had prior inpatient treatment experience. Time since the ibogaine session ranged from 4 weeks to 4 years (mean 17 months). Participants provided informed consent and interviews were ethically approved by Universidade Federal de São Paulo. The therapeutic package combined cognitive therapy and relapse prevention provided at a private clinic, with ibogaine HCl administered in a hospital setting. Inclusion for ibogaine required good general health on routine laboratory checks, absence of psychiatric comorbidity, strong motivation for abstinence, willingness to engage in pre‑ and post‑treatment psychotherapy, and family support. Exclusion criteria included pregnancy, recent surgery, uncontrolled hypertension or diabetes, cardiac arrhythmias, renal or hepatic insufficiency, Alzheimer's and Parkinson's disease. Patients were advised to be abstinent for at least 30 days before ibogaine to avoid pharmacological interactions and to limit social activity for about 7 days afterward. Ibogaine HCl was legally imported and given in a single oral dose, average 15 mg/kg for men and 12 mg/kg for women, with continuous physician monitoring during the acute effects (about 8 hours). Data collection used semi‑structured one‑to‑one interviews conducted by a trained psychologist, audio‑recorded and transcribed verbatim. Interviews lasted about one hour and covered demographics, substance‑use history, previous treatments, family and professional issues, descriptions of subjective experiences during the acute ibogaine effects, and patients' perceptions of how ibogaine influenced their recovery. Selected participant quotes were translated into English for publication.

Most participants were explicit that the ibogaine session played an important role in their recovery, although many stressed that the concurrent cognitive therapy was necessary to integrate and interpret the subjective experience. The analysis produced material mapped to the six pre‑specified domains; the investigators report that the selected categories and emergent discourses were summarised in a table. Family support: Several patients described vivid, eyes‑closed imagery during the acute ibogaine experience that brought childhood memories and family dynamics into awareness. These visualisations led to insights about family patterns of substance use, recognition of parenting failures, regret, and a renewed capacity to assume parental roles. Emotional shifts such as movement from anger and distrust toward acceptance and forgiveness were commonly reported; one participant said the experience enabled him to "regain trust to be a good father". Network/social support: Participants reported increased awareness of how social circles reinforced drug use, distinguishing destructive friendships from supportive relationships. Several described behaviour change in their social networks, withdrawing from drug‑using peers and prioritising relatives and partners; one patient noted that after the experience he now recognises who "really make part of our life." Psychosocial functioning: Patients described imagining or visualising future roles (for example, returning to university or pursuing a career) and reported improvements in attention, reading and concentration. Some returned to or became more engaged in work, reported greater professionalism and motivation, and experienced broadened leisure interests that felt more rewarding than previous drug‑centred activities. Quality of life: Broad improvements in mood, motivation and enjoyment of daily life were commonly reported. Changes included renewed desire to participate in ordinary activities, better eating habits and interest in exercise, and heightened sensory appreciation (food, breathing, being outdoors). One participant described coming back "in pure joy" and a sense of feeling free. Craving: Reductions in craving were reported across substances including tobacco, alcohol, cocaine and crack. For tobacco, several patients described strong nausea and disgust toward cigarette smell; one said smelling cigarettes made him physically sick. Cocaine and crack users described a shift in the way memories of use were experienced, from compulsive wanting to recollections emphasising negative consequences, and some emphasised a restored capacity to choose whether to use. Changes in self‑efficacy: Participants reported greater awareness of personal strengths and limitations, increased capacity for goal‑setting and planning, and improved coping with stress and daily challenges. These changes were framed as increased introspection and decision‑making ability that supported sustained behavioural change. The investigators emphasised that many patients considered the combination of ibogaine and psychotherapy to be synergistic; several said prior treatments had not produced comparable gains.

Ekman Schenberg and colleagues interpret the interview data as indicating that hospital‑administered ibogaine, when combined with cognitive therapy, elicited psychological experiences that patients perceived as producing positive changes across a range of secondary outcomes relevant to drug‑dependence treatment. The findings extend prior reports of ibogaine‑related craving reduction beyond opioid users to include alcohol, tobacco, cocaine and crack users, and suggest benefits in family relations, social networks, professional and educational engagement, nutrition, exercise and overall quality of life. Patients also reported increased self‑efficacy in making choices, setting goals and coping with difficulties. The authors position these results as supportive of ibogaine's therapeutic potential while acknowledging important limitations. Sampling and recruitment were conducted by clinic staff, which may have introduced selection bias, and the small non‑random sample drawn from a setting where ibogaine is unscheduled in Brazil limits generalisability. The treatment comprised multiple components (cognitive therapy, music therapy, yoga, group meetings) so improvements cannot be uniquely attributed to ibogaine; some patients explicitly emphasised the necessity of psychotherapy to process the acute experience. The sample's relatively high socioeconomic and educational status is noted as a factor that can influence outcomes. Safety concerns receive particular attention: ibogaine has known cardiotoxicity related to hERG channel effects and QTc prolongation, and the authors highlight a reported fatality in Brazil in June 2016 that occurred outside the present study. They underline that participants in this report received medical‑grade ibogaine HCl, individually calculated dosing and continuous hospital monitoring, which the authors argue increases safety and trust. Finally, the investigators caution that ibogaine should not be viewed as a standalone cure; willingness to change and sustained behavioural work are necessary for long‑term recovery. They conclude that, given the paucity of effective treatments for psychostimulant dependence, further research into ibogaine's therapeutic potential is warranted but must proceed with caution to minimise the risk of serious adverse events.